RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Rosetta Genomics Stock

Rosetta Genomics Employees 2025

Rosetta Genomics Employees

0

Ticker

ROSGQ

ISIN

IL0011026494

WKN

A0MMDG

In 2025, Rosetta Genomics employed 0 people, a 0% change from the 0 number of employees in the previous year.

Rosetta Genomics Aktienanalyse

What does Rosetta Genomics do?

Rosetta Genomics Ltd is a company specializing in personalized medicine, focused on the development and commercialization of diagnostic tests based on RNA interference and NGS technologies for cancer diseases. The company was founded in 2000 and has its headquarters in Israel, with offices in the USA and Europe. The history of Rosetta Genomics began with the development of MicroRNA (miRNA), RNA molecules that act as regulators of gene expression in cells. The company developed a technology that allows for the identification of specific miRNAs that are characteristic of different types of cancers. As a result, Rosetta Genomics started developing a series of diagnostic tests based on these miRNAs to enable personalized therapy for cancer patients. Rosetta Genomics' business model is based on the commercialization of diagnostic tests for various cancer types. These tests can be requested by doctors and other medical professionals to determine the best treatment for patients. The company works closely with clinicians and researchers to continually improve its tests and stay up to date with the latest technology. The company operates in two main divisions: RosettaGX and RosettaWGX. RosettaGX offers diagnostic tests for various cancer types, including lung cancer, thyroid cancer, and colorectal cancer. These tests utilize Rosetta Genomics' proprietary RNA interference technology to identify specific miRNAs indicative of a particular type of cancer. On the other hand, RosettaWGX offers NGS services that allow researchers and pharmaceutical companies to collect and analyze DNA sequencing data to gain insights into the genetics of cancer. Some of the products offered by Rosetta Genomics include the miRview® Lung Test, miRview® mets2 Test, and miRview® Thyroid Test. The miRview® Lung Test identifies specific miRNAs characteristic of various types of lung tumors to enable an accurate diagnosis. The miRview® mets2 Test can determine the origin of cancer cells that have spread from the primary site, enabling targeted treatment. The miRview® Thyroid Test enables an accurate diagnosis of thyroid cancer and can determine the likelihood of a more aggressive form of the disease. Overall, Rosetta Genomics has developed a wide range of diagnostic tests and services based on a unique technology platform to enable personalized medicine for cancer patients. The company collaborates closely with doctors, researchers, and pharmaceutical companies to continually improve its tests and stay at the forefront of technology. With its innovative products and services, Rosetta Genomics is an important player in the field of personalized medicine and contributes to improving treatment outcomes for cancer patients. Rosetta Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Rosetta Genomics's Employee Base

Rosetta Genomics's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Rosetta Genomics's operational capacity and future potential.

Year-to-Year Comparison

Assessing Rosetta Genomics's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Rosetta Genomics's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Rosetta Genomics’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Rosetta Genomics stock

How many employees does Rosetta Genomics have this year?

Rosetta Genomics has 0 undefined employees this year.

How many employees did Rosetta Genomics have compared to the previous year?

Compared to the previous year, Rosetta Genomics had 0% more employees.

What impact did the number of employees have on the company Rosetta Genomics?

The number of employees has a direct impact on the efficiency and productivity of Rosetta Genomics. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Rosetta Genomics?

The number of employees can also have an impact on investors of Rosetta Genomics, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Rosetta Genomics affect the company?

An increase in equity of Rosetta Genomics can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Rosetta Genomics's equity affect the company?

A reduction in equity of Rosetta Genomics can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Rosetta Genomics?

Some factors that can influence the equity of Rosetta Genomics include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Rosetta Genomics so important for investors?

The equity of Rosetta Genomics is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Rosetta Genomics influence the company?

The number of employees at Rosetta Genomics can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Rosetta Genomics evolved in recent years?

In recent years, the number of employees at Rosetta Genomics has changed by NaN.

How many employees does Rosetta Genomics currently have?

Rosetta Genomics currently has 0 undefined employees.

Why is the number of employees important for investors of Rosetta Genomics?

The number of employees is important for investors of Rosetta Genomics as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Rosetta Genomics take to change the number of employees?

To change the number of employees, Rosetta Genomics can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Rosetta Genomics pay?

Over the past 12 months, Rosetta Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Rosetta Genomics is expected to pay a dividend of 0 USD.

What is the dividend yield of Rosetta Genomics?

The current dividend yield of Rosetta Genomics is .

When does Rosetta Genomics pay dividends?

Rosetta Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Rosetta Genomics?

Rosetta Genomics paid dividends every year for the past 0 years.

What is the dividend of Rosetta Genomics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Rosetta Genomics located?

Rosetta Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Rosetta Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Rosetta Genomics from 7/27/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/27/2025.

When did Rosetta Genomics pay the last dividend?

The last dividend was paid out on 7/27/2025.

What was the dividend of Rosetta Genomics in the year 2024?

In the year 2024, Rosetta Genomics distributed 0 USD as dividends.

In which currency does Rosetta Genomics pay out the dividend?

The dividends of Rosetta Genomics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Rosetta Genomics

Our stock analysis for Rosetta Genomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Rosetta Genomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.